ClinicalTrials.gg

Program

laroprovstat

Also written as “AZD0780”, “FDC laroprovstat/Rosuvastatin 1” and “FDC laroprovstat/Rosuvastatin 2”.

Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Cardiovascular Diseases · Hyperlipidemias · Atherosclerosis, led by AstraZeneca.

Furthest: phase 3, since Dec 2, 202422 company-led studies, 7 open or runningNext primary completion: Jan 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca227 open or runningphase 3since Dec 2, 2024May 17, 2022Jan 4, 2027phase 3 · NCT07000136
  • Named in AstraZeneca’s own pipeline as laroprovstat, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel, fortrea and quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since May 17, 2022.

  1. Sep 23, 2024Phase 1 study in DyslipidemiasNCT06671405 · 59 enrolled · United States
  2. Oct 28, 2024Phase 2 study in AtherosclerosisNCT06692764 · 202 enrolled · United States
  3. Dec 2, 2024Phase 3 study in DyslipidemiasNCT06834932 · 432 enrolled · China, Hong Kong
  4. Dec 16, 2024Phase 1 study in DyslipidemiasNCT06742853 · 81 enrolled · United States, United Kingdom
  5. May 23, 20253 phase 3 studiesNCT07000136, NCT07000123, NCT07000357
  6. Oct 10, 2025Phase 1 study in DyslipidemiasNCT07216131 · 14 enrolled · United States
  7. Oct 17, 2025Phase 2 study in DyslipidemiasNCT07218900 · 76 enrolled · Russia
  8. Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07316608 · 44 enrolled · United States
  9. Feb 13, 2026Phase 1 study in DyslipidemiasNCT07423598 · 40 enrolled · United States
  10. Mar 31, 2026Phase 1 study in DyslipidemiasNCT07513571 · 31 enrolled · United States
  11. May 26, 20262 phase 3 studies in HypercholesterolemiaNCT07619131, NCT07619118
  12. May 28, 2026Phase 1 study in HyperlipidemiasNCT07622433 · 18 enrolled · United States
  13. Nov 5, 2026Phase 3 study in HypercholesterolemiaNCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
  14. Nov 13, 2026Primary completion moved from 2025-07-03 to 2027-02-22Date moved laterphase 3 · +20 months · NCT06834932

Ahead

  1. Jan 4, 2027Primary completion: phase 3 study in Heterozygous Familial HypercholesterolaemiaNCT07000136
  2. Jan 11, 2027Primary completion: phase 3 study in Cardiovascular DiseasesNCT07000123
  3. Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasNCT06834932
  4. May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaNCT07619118

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more3Not yet recruitingOct 11, 2027204
NCT07622433Hyperlipidemias · United States1CompletedSep 6, 202618
NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more3RecruitingJul 30, 2027600
NCT07619118Hypercholesterolemia · United States, Australia, Canada and more3RecruitingMay 28, 2027200
NCT07513571Dyslipidemias · United States1CompletedJul 8, 202631
NCT07423598Dyslipidemias · United States1CompletedJun 29, 202640
NCT07316608Hyperlipidemias · United States1CompletedJun 5, 202644
NCT07218900Dyslipidemias · Russia2CompletedSep 3, 202676
NCT07216131Dyslipidemias · United States1CompletedDec 30, 202514
NCT07000357Cardiovascular Diseases · United States, Argentina, Brazil and more3RecruitingOct 26, 202915,100
NCT07000136Heterozygous Familial Hypercholesterolaemia · United States, Argentina, Australia and more3Active, not recruitingJan 4, 2027473
NCT07000123Cardiovascular Diseases · United States, Argentina, Australia and more3Active, not recruitingJan 11, 20273,103
NCT06742853Dyslipidemias · United States, United Kingdom1CompletedOct 29, 202581
NCT06834932Dyslipidemias · China, Hong Kong3Active, not recruitingFeb 22, 2027432
NCT06692764Atherosclerosis · United States2CompletedApr 18, 2025202
NCT06671405Dyslipidemias · United States1CompletedFeb 17, 202559
NCT06576765Hepatic Impairment · United States1CompletedNov 8, 202416
NCT06592482Renal Insufficiency · United States1CompletedDec 1, 202430
NCT06173570Dyslipidemias · United States, Canada, Czechia and more2CompletedSep 30, 2024428
NCT05817461Cardiovascular Diseases · United Kingdom1CompletedJun 6, 20238
NCT05787002Dyslipidemias · United States1CompletedMay 15, 202316
NCT05384262Dyslipidemias · United States, United Kingdom1CompletedJun 14, 2024183

How it is read

Names in the registry

  • “AZD0780”, 17 entries
  • “FDC laroprovstat/Rosuvastatin 1”, 1 entry
  • “FDC laroprovstat/Rosuvastatin 2”, 1 entry
  • “laroprovstat/rosuvastatin 1”, 1 entry
  • “laroprovstat/rosuvastatin 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.